Currently, ECP is developing a percutaneous, expandable catheter pump that offers a potential flow rate of up to 4.5l per minute, and an insertion radius for the impeller and catheter of less than 10 French.
ECP holds patents or patent applications in over 40 patent families, valid with expirations up to year 2033. These patents will be added to the approximately 100 patents and patent applications from the Impella device.
Abiomed said that the acquisition of ECP is consistent with the company’s strategy to offer percutaneous hemodynamic support for minimally invasive procedures for complex treatment. The acquisition will also strengthen its in intellectual property (IP) for axial and expandable pump capabilities.
Abiomed, in connection with the transaction, acquired all outstanding shares of ECP from Syscore for approximately $13m in cash, with potential long-term payouts of $7m for CE Marking approval and $8m for achieving aggregate worldwide revenue of $125m for products utilizing ECP patents.
The company has also acquired through ECP, AIS GmbH Aachen Innovative Solutions, the owner of certain IP rights related to ECP’s development efforts, for approximately $2.75m.
